Among these drugs and therapies, the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade is a newly raised cancer immunotherapy for cancer treatment, and the related drugs are under development for the clinical treatment of NSCLC [7, 8]. Here, CD274 is linked to non-small cell lung carcinoma.